model was inadequate in relating HM-PAO uptake to LCBF. A better HM-PAO uptake-LCBF correlation was obtained when the HM-PAO arterial input function was corrected for very rapidly produced, non-cerebrally ex tracted, metabolites and a kinetic model was used that considered the rate of intracerebral metabolism of HM PAO to a retained metabolite. Even using this model, however, some differences between HM-PAO uptake and LCBF occurred in certain brain regions. Because these differences were small and the HM-PAO uptake pattern has been shown to be constant for many minutes, HM PAO can probably be used to estimate LCBF in patients with single positron emission computed tomography (SPECT) imaging. Key Words: HM-PAO-99mTC LCBF.
Summary:
The cerebral uptake of [99mTc]-d,l-hexa methylpropyleneamine oxime complex (HM-PAO) was compared to LCBF determined simultaneously with P4C]iodoantipyrine (lAP) using double radio nuclide quantitative digital autoradiography. Awake male rats were given intravenous injections of a mixture of 50 fLCi lAP and 15 mCi of HM-PAO and killed 20 s after tracer activity had first reached the brain. Two separate autoradiograms were produced from each 20 fLm brain section. The autoradiograms were digitized, corrected for cross-contamination, and then converted into images of individual tracer concentration. The diffusible tracer model was used to convert the lAP concentration images into LCBF images. Regional HM-PAO concentration was found not to be linearly related to LCBF as determined with the lAP, and therefore a simple microsphere type [99mTc]-d,l-hexamethylpropyleneamine oxime complex (HM-PAO) is a member of a family of compounds that have been shown to have high and persistent cerebral uptake in animals and humans following intravenous administration (Holmes et a1., 1985; N owotnik et a1., 1985; Sharp et a1., 1986) . Distribution patterns have been shown to be stable in rats for over 30 min (Neirinckx et a1., 1987; Hoffman et aI., 1988) . Preliminary work has also suggested that cerebral distribution may reflect LCBF (Volkert et aI., 1986; Steiner et aI., 1986; Lear, 1988) , although details of the relationship be tween uptake and LCBF have not been well de fined. We therefore decided to evaluate this rela tionship further by comparing HM-PAO distribu tion in the brain with LCBF values determined simultaneously with e4C]iodoantipyrine (lAP) us ing double label quantitative digital autoradiogra phy. Specifically, a new kinetic model which con siders the rate of intracerebral metabolism of HM PAO to a retained metabolite (Lassen et aI, 1988) was applied to the HM-PAO uptake data.
METHODS
The study was performed in a series of six awake, male rats. Polyethelyne catheters were inserted into the femo ral arteries and veins of the rats while they were under halothane anesthesia. The rats were then immobilized and allowed to recover for 2 h prior to tracer admin istration.
HM-PAO was prepared by adding 30 mCi of [99mTc]pertechnetate in 2-3 ml saline to the contents of a commercial kit (Amersham International, Buckingham shire, England). The [99mTc]pertechnetate was obtained from a generator that had been pre-eluted 4-8 h earlier to minimize the amount of carrier [99mTc]pertechnetate. lAP was obtained commercially (American Radiolabeled Chemicals, St. Louis, MO, U.S.A.). Within 10 min of preparation of the HM-PAO, the tracers were mixed and used in the infusions. Paper chromatography was used to measure the radiochemical purity of the HM-PAO solu tion (Sharp et al. , 1986) .
Thirty second intravenous infusions of approximately 15 mCi HM-PAO and 50 J.l.Ci of lAP were administered and the rats were killed by rapid KCI injection and de capitation at the end of the infusions. (This infusion schedule was chosen to produce arterial tracer input func tions of approximately 20 s duration so as to minimize back-diffusion effects on lAP uptake. ) Arterial blood samples were obtained at approximately 3 s intervals dur ing the infusions. The brains were rapidly removed and frozen in powdered dry ice. The brains were then sec tioned into 20 J.l.m thick slices using a cryomicrotome, placed on glass cover slips, and dried on a hot plate.
Two autoradiograms were produced from each section so that each autoradiogram would primarily reflect the cerebral concentration of one of the tracers. The sections were placed against Kodak NMB or NMC film and a first exposure of 6-9 h duration was made, which primarily was caused by [99mTc]-HM-PAO decay. Next, the sec tions were removed from the film for 3 days to allow most of the remaining 99mTc (6 h half-life) to decay. Finally, they were placed on a second piece of film and a 7-10 day exposure was made that resulted from 14C (lAP) decay. These times were chosen to optimize separation of expo sures of the different radionuclides (Lear et al. , 1984) and to produce images with darknesses optimized for quanti tative determination of tracer concentration (Lear, 1986) . Calibrated 14C standards were placed on the film adjacent to the sections to allow quantitation of exposure.
Arterial concentration curves of the tracers were gen erated by measuring the activities of 50 J.l.I aliquots of blood in "y and liquid scintillation counters. Paper chro matography was used to determine the fraction of 99mTc label as free pertechnetate, HM-PAO, and nonlipophilic compounds in the arterial samples (Sharp et al. , 1986) .
The autoradiograms were digitized into 512 x 512 ma trices of pixels using a solid state image analyzer devel oped specifically for quantitative autoradiography ) (Scientific Imaging, Inc., Santa Clara, CA, U.S.A.). Using density-exposure curves from the calibrated 14C standards, the original autoradiographic images were converted into equivalent 14C exposure im ages. Cross-contamination between exposures was calcu lated and subtracted pixel by pixel, yielding images rep resenting concentrations of the individual radionuclides.
The lAP concentration images were then converted into LCBF images ( Fig. lA) using data from the arterial curves and the diffusible tracer model (Kety, 1951; Sakurada et al. , 1978) . Exchange across brain capillaries was assumed to be a first order process in which unidi rectional flux of tracer is equal to the product of concen tration and a rate constant:
assuming complete brain-blood equilibrium, i. e. , E = 1, and
where Cb = brain tracer concentration, F = local cere- 1988 bral blood flow, Ca = arterial blood tracer concentration, T = time of death, Kl = blood to brain clearance con stant, k2 = brain to blood rate constant, E = first pass extraction or fractional blood-brain chemical equilibrium per pass, and A = brainlblood partition coefficient.
Because of the previously observed high and persistent cerebral uptake of HM-PAO, the tracer has been consid ered as a potential "chemical microsphere," i.e., its up take and retention would linearly reflect LCBF. To test this hypothesis, therefore, the microsphere model, or tracer fractionation technique (Sapirstein, 1958) , was ini tially applied to the HM-PAO uptake images to generate LCBF images ( Fig. IB) :
assuming complete first pass extraction, and
LCBF values that were obtained for each of the tracers were then compared. For each pixel in the LCBF images, a pair of flow values, one for lAP and one for HM-PAO, was generated and plotted by the computer. This resulted in a plot containing over 200,000 points for each tissue section analyzed. Typically, five representative sections for each animal were compared in this manner and the results were summed, yielding a final plot with over 1,000,000 points ( Fig. 2A) . The data from the six animals was then pooled and a mean value plot was generated ( Fig. 2C ).
Further analysis was performed by creating images in which LCBF values for each tracer were assigned a par ticular color scale in one of two computers and the data from both computers was displayed simultaneously in a single monitor ( Fig. lD) .
Because LCBF values determined with HM-PAO us ing the microsphere model differed significantly from cor responding LCBF values using lAP (see the Results sec tion), LCBF values for HM-PAO were recalculated using a different model. The new model included two important modifications. First, the arterial input function for HM P AO was corrected to account for rapidly produced, non cerebrally extracted metabolites and for binding of a por tion of the HM-PAO to blood constituents. This change was accomplished by including a constant less than 1 that represented the fraction of arterial activity that was free, exchangeable HM-PAO in the kinetic model. Also, the possibility that the compound retained by the brain was not HM-PAO, but rather a metabolite, was included (Las  sen et al., 1987, 1988) . The model was therefore also mod ified to include the rate of intracerebral metabolism of theHMPAO to the retained metabolite. The HM-PAO it self was assumed to be freely exchangeable with a parti tion coefficient near unity: . .:/ , ;
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where Cb l = brain concentration of HM-PAO, Cb2 = brain concentration of the trapped metabolite, Cb = brain total radioactivity concentration, k3 = rate of conversion of HM-PAO to metabolite, Ca = arterial HM-PAO con centration, Cr = arterial total radioactivity concentra tion, and p = factor correcting for radioactive, non- cerebrally extracted, HM-PAO metabolites in the arterial blood.
Values for ex of 0.5, 1,2,3, and 4 were then tested in the modified kinetic model. Mean value plots were generated and examined for linearity. Using this model, LCBF im ages for HM-PAO (Fig. IC) as well as corresponding su perimposition images (Fig. IE) and ratio images (Fig. IF) were created.
RESULTS
Chromatography of the injectants indicated that approximately 90% of the 99mTc was in the form of HM-PAO and that the preparation was stable in the vial, either alone or mixed with lAP, for at least 30 min. Chromatography of the blood samples, how ever, indicated that rapid conversion of lipophilic HM-PAO to a nonlipophilic compound occurred. The conversion was so rapid that most of the 99mTc was in that form by the time the blood samples could be prepared for chromatography. It was therefore impossible to determine experimentally the exact amount of arterial blood activity that rep resented lipophilic HM-PAO as it passed through the brain using the paper chromatographic tech nique.
U sing the microsphere model and arterial curves for the HM-PAO in which total HM-PAO activity was corrected only for initial radiochemical purity, mean LCBF values using HM-PAO were signifi cantly less (63 ± 5%) than those of lAP. The rela tionship of HM-PAO LCBF compared to lAP LCBF was fairly linear for values through approx imately 100 ml/100 g/min, but the relative underes timation then increased slightly with increasing val ues of LCBF ( Fig. 2A) .
A better linear relationship between LCBF val ues with HM-PAO and lAP could be obtained with the model proposed by Lassen et ai. Optimum lin earization, as determined by visual inspection of the HM-PAO LCBF vs. lAP LCBF mean value graphs, was found when a value of approximately 2 was used for (l. Using this value, the slope of the HM PAO LCBF vs. lAP LCBF line, i.e., p, measured 0.7, suggesting that approximately 30% of the orig inal HM-PAO in the injectant had been converted to a non-cerebrally extracted compound or was other wise unavailable for exchange during the 30 s ex perimental period. Final plots of LCBF using HM PAO corrected for (l (2) and p (0.7) are shown in Figs. 2B and 2C.
After the correction of HM-PAO LCBF values as described above, some differences between these values and lAP LCBF values persisted in certain regions (Figs. IE and IF) . LCBF values in white matter (such as the external capsule) and adjacent structures were lower with HM-PAO compared to those measured with lAP. HM-PAO LCBF images showed a more heterogeneous pattern in gray mat ter structures than comparable images obtained with lAP. A few regions showed relatively high flow with HM-PAO.
DISCUSSION
HM-PAO was shown to underestimate LCBF by approximately 40% compared to lAP using the mi crosphere model with the arterial input corrected only for radiochemical purity of the injectant. The underestimation progressed slightly with increasing LCBF.
A better linear relationship between LCBF val ues of the two tracers could be obtained by using the model proposed by Lassen et al. The model assumes that the compound that is retained by the brain is a metabolite of HM-PAO formed within the brain and that the HM-PAO itself is freely ex changeable between the blood and the brain. For simplicity, Lassen et al. recommended that the brain-blood partition coefficient for the HM-PAO be assumed to be equal to 1 and that the metabolite be assumed to have perfect retention once formed. This type of model could certainly explain much of the observed behavior of the HM-PAO in this study. If (l is high compared to median values of flow, then its effects would be expected to be seen only at the upper end of the LCBF range. The ob servation in this study that nonlinearities between HM-PAO concentration and LCBF did not occur until a LCBF value of approximately 100 is in agree ment with this prediction. Also, the (l value of 2 found in this study is in good agreement with esti mates based on comparison of LCBF measured with HM-PAO using single positron emission com puted tomography (SPECT) and [015] water using positron emission tomography (PET) (Yonekara et aI., 1988; Langen et aI., 1988) .
After linearization, the slope of the HM-PAO LCBF vs. lAP LCBF relationship measured ap proximately 0.7, indicating that only 70% of the in jected HM-PAO was available for extraction by the brain. This very rapid loss of exchangeable HM PAO from the blood could be caused by rapid con version to nonlipophilic metabolites and/or binding to some blood constituent (Lavender et aI., 1987; Lui et aI., 1987) . The effective in vivo radiochemi cal purity factor of 0.7 found in this study is close to the value of 0.8 measured with immediate separa tion of HM-PAO from arterial blood using octanol extraction (Andersen et al., 1988) .
In addition to the flow-dependent differences al ready described, the ratio imaging and multicolor image superimposition demonstrated apparently non-flow-dependent differences in uptake patterns (Figs. IE and IF) . While the causes of these dis crepancies are more difficult to define than those related to LCBF, some reasonable possibilities can be suggested. For example, HM-PAO underesti mated LCBF compared to that obtained with lAP in some white matter and adjacent structures using ei ther the microsphere or corrected kinetic models. A common assumption between the two models is that all parts of the brain are exposed to the same arterial input function. Because arteries and arteri oles pass inward from the cortex to the deeper white matter structures, any tracer that is lost dur ing transit will result in lower blood concentration reaching the deeper structures. A similar effect could also explain the heterogeneous pattern of HM-PAO uptake. The proximal ends of the arteri oles could have higher tracer concentrations than the distal ends, so more activity would occur adja cent to the arterioles than between them. This could create an "arteriolar" pattern, such as that ob served with isopropyliodoamphetamine and iodo amphetamine (Lear et aI., 1987; Rapin et aI., 1984) . Because lAP is not trapped and has a brain-blood partition coefficient of less than 1, such a pattern would not be expected at 20 s, by which time "downstream" diffusion effects could smooth the tracer distribution pattern. In fact, we have ob served an arteriolar pattern with lAP when using very short injection times, less than 10 s, and im mediate liquid nitrogen freezing of the brain. If this supposition is correct, it raises the possibility of minor flow-dependent inaccuracies in using lAP and the diffusible tracer model.
The existence of cerebral regions with relatively high HM-PAO LCBF/IAP LCBF values (Figs. IE and IF) could be explained by variations in regional functional capillary density that do not correspond exactly to normal LCBF distribution. Such differ ences could cause corresponding variations in blood velocity through the capillaries that in turn could cause variable regional extraction at high flow values. Thus, the assumption of chemical equilib rium between the brain and venous blood used in the diffusible tracer model might not apply in some areas whose capillary density is relatively low com pared to baseline LCBF. This could cause an un derestimation of LCBF by lAP, an observation sup ported by comparison of values obtained with lAP and diethyldithiocarbamate (Lear, 1988 ). An alter native explanation of these apparently non flow-dependent differences in distribution of lAP and HM-PAO is that the rate of metabolism of HM PAO to a retained metabolite, k3' varies regionally.
In conclusion, a relationship can be defined that generally relates cerebral HM-PAO uptake to LCBF as measured by lAP. Reverse application of the relationship to the determination of LCBF using HM-PAO in clinical situations, however, is compli cated by the large and potentially variable correc tion factor for loss of arterial HM-PAO purity through rapid metabolism or blood constituent binding. Nevertheless, the observation in this study that nonlinearities in the initial HM-PAO distribu tion vs. LCBF are not extreme and can be corrected J Cereb Blood Flow Metab, Vol. 8, Suppl. 1, 1988 as suggested by Lassen et aI., indicate that HM PAO distribution following intravenous administra tion can be used to depict regional cerebral perfu sion with SPECT imaging.
